Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose HPV vaccine immunogenicity and safety in girls aged 9–14
ChiCTR2300069209Phase 4Recruiting
- Sponsor
- Fujian Provincial Center for Disease Control and Prevention
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in Cervical Cancer (CC) and human papillomavirus infection comparing Cecolin single-dose arm with Gardasil single-dose arm (2 arms). Primary endpoint: Sero-conversion rate of neutralizing antibodies to HPV16 and HPV18. Started Feb 2023; status: recruiting.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccineqHPV vaccine
03
Conditions
Cervical Cancer (CC)human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2300069209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069209.